- Home
- AMGN vs LOW Comparison
AMGN vs LOW Comparison
Compare AMGN & LOW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMGN
- LOW
- Stock Information
- Founded
- AMGN 1980
- LOW 1946
- Country
- AMGN United States
- LOW United States
- Employees
- AMGN N/A
- LOW N/A
- Industry
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- LOW RETAIL: Building Materials
- Sector
- AMGN Health Care
- LOW Consumer Discretionary
- Exchange
- AMGN Nasdaq
- LOW Nasdaq
- Market Cap
- AMGN 156.2B
- LOW 127.8B
- IPO Year
- AMGN N/A
- LOW N/A
- Fundamental
- Price
- AMGN $277.29
- LOW $219.00
- Analyst Decision
- AMGN Buy
- LOW Buy
- Analyst Count
- AMGN 20
- LOW 24
- Target Price
- AMGN $324.32
- LOW $279.67
- AVG Volume (30 Days)
- AMGN 3.7M
- LOW 3.2M
- Earning Date
- AMGN 05-01-2025
- LOW 05-20-2025
- Dividend Yield
- AMGN 3.43%
- LOW 2.10%
- EPS Growth
- AMGN N/A
- LOW N/A
- EPS
- AMGN 7.56
- LOW 12.23
- Revenue
- AMGN $33,424,000,000.00
- LOW $83,674,000,000.00
- Revenue This Year
- AMGN $7.36
- LOW $1.90
- Revenue Next Year
- AMGN $2.30
- LOW $3.60
- P/E Ratio
- AMGN $36.68
- LOW $17.91
- Revenue Growth
- AMGN 18.57
- LOW N/A
- 52 Week Low
- AMGN $253.30
- LOW $206.39
- 52 Week High
- AMGN $346.85
- LOW $287.01
- Technical
- Relative Strength Index (RSI)
- AMGN 36.23
- LOW 42.69
- Support Level
- AMGN $267.40
- LOW $213.30
- Resistance Level
- AMGN $296.17
- LOW $225.60
- Average True Range (ATR)
- AMGN 12.41
- LOW 8.74
- MACD
- AMGN -2.02
- LOW -0.03
- Stochastic Oscillator
- AMGN 20.78
- LOW 42.43
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
About LOW Lowe's Companies Inc.
Lowe's is the second-largest home improvement retailer in the world, operating more than 1,700 stores in the United States, after the 2023 divestiture of its Canadian locations (RONA, Lowe's Canada, Réno-Dépôt, and Dick's Lumber). The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a high-single-digit share of the domestic home improvement market, based on U.S. Census data and management's market size estimates.